VivoSphere
VivoSphere is a privately held biotech company developing 3D tissue-engineered in vitro models — built on proprietary high-density cell encapsulation and microfluidic fabrication — for drug discovery and toxicity testing by pharmaceutical, biotechnology, academic, and CRO customers.
- Company typePrivate
- Founded2019
- HeadquartersAuburn, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What VivoSphere does
VivoSphere is a privately held biotechnology company headquartered at the Auburn University New Venture Accelerator in Auburn, Alabama, with a regional subsidiary (VivoSphere UK) launched in 2024. The company develops 3D tissue-engineered models for in vitro drug discovery and toxicity testing, built around a proprietary high-density cell encapsulation method and a microfluidic fabrication platform that the co-founders co-invented. Its product surface spans standardized 3D cell culture models, pre-validated assay-ready tissues, customizable hydrogel-based tissue microenvironments, and custom model development services, with explicit compatibility for high-throughput screening and lab automation workflows.
The company sells to pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and — at the exploratory end — healthcare providers pursuing precision-medicine applications. Pricing is not publicly disclosed; the company runs a direct, quote-based enterprise sales motion supplemented by academic-industry partnerships (notably with Auburn University), industry conferences (BIO, SLAS, AACR, BioAlabama, MPS World Summit), and accelerator programs (Gener8tor, Hatch/Bessel). VivoSphere has funded operations exclusively through non-dilutive grants — including NSF I-Corps, NSF Phase I STTR, a $350K NIH award, Alabama Launchpad, and Innovate Alabama — and remains in a pre-commercial or very early-commercial stage with a 1–10 person team led by co-founders Dr. Elizabeth Lipke (CSO) and Dr. Yuan Tian (CTO).
VivoSphere firmographics
Firmographics- Name
- VivoSphere
- Legal name
- VivoSphere, LLC
- Website
- https://vivospheres.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- VivoSphere is a privately held biotech company developing 3D tissue-engineered in vitro models — built on proprietary high-density cell encapsulation and microfluidic fabrication — for drug discovery and toxicity testing by pharmaceutical, biotechnology, academic, and CRO customers.
- Ownership category
- akta.pro rank
VivoSphere industry classification
Industry- Product category
- 3D Tissue-Engineered Cell Culture Models
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where VivoSphere is headquartered
LocationHeadquarters
- HQ city
- Auburn
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
VivoSphere business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- 3D Cell Culture Models and Assay-Ready Tissues: Sale of standardized 3D tissue-engineered models and pre-validated assay-ready tissues for drug discovery and toxicity testing. These are sold as products with direct sales engagement to pharmaceutical and biotech companies.
- Custom Model Development Services: Tailored 3D tissue model development services for specific research needs in oncology, toxicology, and regenerative medicine applications.
- Research Collaborations & Partnerships: Collaborative research arrangements with universities, biotech firms, and pharmaceutical companies for joint development of advanced in vitro models and tissue engineering solutions.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
VivoSphere product offering
Product offeringCore offering
VivoSphere develops and manufactures 3D tissue-engineered models and assay-ready tissues for pharmaceutical, biotechnology, and academic research customers conducting in vitro drug discovery and toxicity testing. The company combines proprietary high-density cell encapsulation with a microfluidic fabrication platform to produce physiologically relevant tissue microenvironments that are more predictive than traditional 2D cultures. Revenue is generated through direct product sales of standardized models, custom model development services, and collaborative research engagements.
Product overview
VivoSphere is a biotech company offering a portfolio of 3D tissue-engineered models for in vitro drug discovery and toxicity testing. The core offerings consist of 3D Cell Culture Models, Assay-Ready Tissues, and Customized Solutions, supported by Tissue Engineering & High-Throughput Screening Services and Custom Model Development. These products provide physiologically relevant alternatives to traditional 2D cultures and animal testing, enabling researchers to generate more human-like tissue responses for improved preclinical data translatability.
Differentiator
Problem solved
Functional benefit
Products and services
- 3D Cell Culture Models Standardized 3D tissue-engineered cell culture models that replicate natural tissue microenvironments, enhancing cell-to-cell interactions and improving drug discovery accuracy and toxicity testing predictability for pharmaceutical, biotech, and academic researchers.
- Assay-Ready 3D Tissues Pre-validated, ready-to-use 3D tissue products designed for high-throughput drug screening and toxicity testing, providing physiologically relevant data with reliability, scalability, and compatibility with laboratory automation systems.
- Custom Model Development Services Custom 3D tissue model development services tailored to specific research needs using advanced bioengineering techniques, including tailored microenvironments for disease modeling, oncology research, regenerative medicine, and tissue engineering and high-throughput screening programs.
Quantifiable outcome
- Enhanced drug responses observed in 3D tumor models compared to traditional 2D cultures
- +2 more outcomes
Companies that use VivoSphere
Customer profileSegments5 records
Ideal customer profiles4 records
VivoSphere technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
VivoSphere partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Hatch Fairhope / BesselcoreVivoSphere participated in the Hatch Powered by Bessel second annual biotech and medtech accelerator program, a 12-week program delivering 240+ hours of mentorship. The program supports companies across two years totaling 432+ hours of direct mentorship and positions the Gulf Coast as a emerging biotech hub.
- Gener8torcoreVivoSphere is participating in the Gener8tor gBETA accelerator program Spring 2026 focused on health technology innovation. Gener8tor is a nationally ranked accelerator that provides mentorship, capital, and network access to startups.
- Society for Laboratory Automation and Screening (SLAS)minorVivoSphere was nominated for the 2024 SLAS Ignite Award and selected as SLAS2024 Innovation AveNEW company for meeting at the SLAS2024 International Conference & Exhibition in Boston.
- Auburn University / AU New Venture AcceleratorcoreVivoSphere is based at AU New Venture Accelerator in Auburn, AL. The company originated from Auburn University Chemical Engineering faculty research. Dr. Elizabeth Lipke and Dr. Yuan Tian are Auburn University faculty co-founders. Featured by Auburn University College of Engineering news and Auburn University New Venture Accelerator.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
VivoSphere competitors and assessment
Company assessmentDirect peers
- InSphero: InSphero commercializes 3D microtissue models (liver, pancreatic islet, tumor) for drug discovery and toxicity testing — the most direct comparator to VivoSphere's 3D cell culture / assay-ready tissue business.
- Mimetas: Mimetas sells the OrganoPlate platform for organ-on-chip and 3D tissue models used in pharma preclinical screening; comparable in technology (microfluidic 3D cultures) and customer base (big-pharma toxicology/screening groups).
- CN Bio Innovations: CN Bio offers single- and multi-organ microfluidic chips (PhysioMimix) for drug discovery and toxicity testing, directly overlapping with VivoSphere's microfluidic encapsulation-based preclinical platform.
- Emulate: Emulate's organ-on-chip platform replicates human tissue responses for pharma R&D; a scaled direct competitor pursuing the same pharma/biotech preclinical screening accounts.
- TissUse: TissUse develops multi-organ-chip systems for ADME, toxicity, and disease modeling — a direct peer in microfluidic 3D tissue engineering for pharma preclinical applications.
- SynVivo: SynVivo provides microfluidic organ-on-chip and tumor-on-chip models for drug delivery and toxicity studies; comparable in microfluidic tissue modeling for preclinical research.
Broad incumbents
- Organovo: Organovo is a publicly listed 3D bioprinting company developing human tissue constructs for therapeutic and research use — a broader incumbent in the 3D tissue-engineering category encompassing VivoSphere's niche.
Emerging players
- Hurel Corporation: Hurel builds in vitro microfluidic tissue models for ADME-Tox testing, focused on liver and other organ models; an emerging player with overlapping technology and customer segments.
- DefiniGEN: DefiniGEN provides iPSC-derived human cell models (hepatocytes, pancreatic) for drug discovery and metabolic disease research — adjacent in the in vitro human-cell-model space.
Others
- CytoSMART: CytoSMART provides live-cell imaging and automated cell culture monitoring hardware — an adjacent enabling technology supplier to 3D tissue / organ-on-chip workflows rather than a direct competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
VivoSphere social profiles
Digital presenceVivoSphere financial estimates
Financial estimateRevenue estimate
Valuation estimate
VivoSphere leadership team
Management profileNumber of profiles
Profiles10 records
VivoSphere subsidiaries and ownership
Company hierarchySubsidiaries1 record
VivoSphere funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VivoSphere M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VivoSphere
What does VivoSphere do?
VivoSphere develops and manufactures 3D tissue-engineered models and assay-ready tissues for pharmaceutical, biotechnology, and academic research customers conducting in vitro drug discovery and toxicity testing. The company combines proprietary high-density cell encapsulation with a microfluidic fabrication platform to produce physiologically relevant tissue microenvironments that are more predictive than traditional 2D cultures. Revenue is generated through direct product sales of standardized models, custom model development services, and collaborative research engagements.
Is VivoSphere a public or private company?
VivoSphere is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was VivoSphere founded?
VivoSphere was founded in 2019. It employs 1 to 10 people.
Where is VivoSphere based?
VivoSphere is headquartered in Auburn, United States, in the North America region.
How does VivoSphere make money?
Three revenue lines are on record. 3D Cell Culture Models and Assay-Ready Tissues are the primary driver. The others are custom Model Development Services and research Collaborations & Partnerships.
Who are VivoSphere's main competitors?
Direct peers on record are InSphero, Mimetas, CN Bio Innovations, Emulate, TissUse and SynVivo. Organovo is listed as a broad incumbent. Emerging players are Hurel Corporation and DefiniGEN. CytoSMART is listed as an others.
Does VivoSphere have an API?
No public API is recorded for VivoSphere.
What industry is VivoSphere in?
VivoSphere's product category is 3D Tissue-Engineered Cell Culture Models. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.